ERBB2 and breast cancer: We hypothesised that the ability of the CPK technology to provide relatively high numbers of CTCs and allow robust FISH analysis would facilitate the determination of the relationship between the HER2 status of a patients primary breast cancer, metastatic lesions, and CTCs.